肥胖与接受连续肾脏替代治疗的急性肾损伤危重患者肾脏结局之间的关联:多中心CRRTnet研究的二次分析
该研究为多中心前瞻性观察性CRRTnet研究的二次分析,纳入890例接受CRRT的AKI危重成人(排除CRRT<24小时者)。肥胖组478例与非肥胖组412例的住院死亡率相似(53.8% vs 52.4%,p=0.74),但多变量分析中肥胖独立与死亡率升高相关(adj-OR 1.53;95%CI 1.03–2.28;p=0.034)。处方CRRT剂量强度每增加5 mL/kg/h,按实际体重、理想体重和调整体重指数计算均与住院死亡率升高相关(adj-OR分别为1.17、1.13、1.19)。作者认为这些发现提示可能需要调整肥胖患者的CRRT处方实践,并需进一步研究最佳CRRT剂量强度。
要点
- 在890例接受CRRT的AKI危重成人中,肥胖(BMI≥30 kg/m2)与非肥胖患者住院死亡率相似(53.8% vs 52.4%,p=0.74)。
- 多变量分析中,肥胖独立与住院死亡率升高相关(adj-OR 1.53;95%CI 1.03–2.28;p=0.034)。
- 处方CRRT剂量强度每增加5 mL/kg/h,按实际体重计算与住院死亡率升高相关(adj-OR 1.17;95%CI 1.10–1.25;p<0.001)。
- 按理想体重和调整体重计算的处方CRRT剂量强度每增加5 mL/kg/h,也均与住院死亡率升高相关(adj-OR分别为1.13和1.19)。
- 作者认为这些发现提示可能需要调整肥胖患者的CRRT处方实践,并需进一步研究最佳CRRT剂量强度。
适用人群与场景
- 危重成人急性肾损伤患者,接受连续肾脏替代治疗(CRRT),排除CRRT治疗时间<24小时者。
- 肥胖定义为体重指数(BMI)≥30 kg/m2,非肥胖定义为BMI<30 kg/m2。
诊断标准与关键阈值
- 肥胖:体重指数(BMI)≥30 kg/m2;非肥胖:BMI<30 kg/m2。
研究设计与关键结果
- 研究类型:多中心前瞻性观察性CRRTnet研究的二次分析;样本量890例(肥胖组478例,非肥胖组412例)。
- 肥胖组中位BMI为36.3 kg/m2(IQR 32.9–41.7),非肥胖组为25.5 kg/m2(IQR 23.3–27.8),p<0.001。
- 住院死亡率肥胖组53.8% vs 非肥胖组52.4%(p=0.74)。
- 多变量分析:肥胖独立与住院死亡率升高相关(adj-OR 1.53;95%CI 1.03–2.28;p=0.034)。
- 处方CRRT剂量强度每增加5 mL/kg/h,按实际体重计算与住院死亡率升高相关(adj-OR 1.17;95%CI 1.10–1.25;p<0.001)。
- 按理想体重计算:adj-OR 1.13(95%CI 1.09–1.18;p<0.001)。
- 按调整体重计算:adj-OR 1.19(95%CI 1.13–1.27;p<0.001)。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察性研究的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现提示可能需要调整肥胖患者的CRRT处方实践。
- 作者认为,需要进一步研究广泛危重患者群体中的最佳CRRT剂量强度处方。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Continuous renal replacement therapy (CRRT) is frequently utilized in critically ill adults with acute kidney injury (AKI). Outcomes among obese patients receiving CRRT, however, are poorly characterized, and the modifying effect of CRRT dose-intensity remains uncertain. This study examined the association between obesity and mortality among critically ill adults receiving CRRT and whether the method used to calculate body weight modified the association between prescribed CRRT dose-intensity and mortality. METHODS: We conducted a secondary analysis of the prospective, multicenter observational CRRTnet study, which enrolled critically ill adults with AKI receiving CRRT. Patients who received < 24 h of CRRT were excluded. Primary outcomes were in-hospital mortality, compared between obese (body mass index [BMI] ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2) patients, and by prescribed CRRT dose-intensity determined by actual body weight (ABW), ideal body weight (IBW), and adjusted-body weight (Adj-BW). RESULTS: Among 890 patients (478 obese and 412 non-obese), median BMI was 36.3 kg/m2 (interquartile range [IQR], 32.9–41.7) for obese and 25.5 kg/m2 (IQR, 23.3–27.8) for non-obese patients (p < 0.001). In-hospital mortality was similar between groups (53.8% vs. 52.4%; p = 0.74). In multivariable analysis, obesity was independently associated with increased mortality (adjusted-odds ratio [adj-OR], 1.53; 95% confidence interval [CI], 1.03–2.28; p = 0.034). Greater prescribed CRRT dose-intensity (per 5 mL/kg/h increase) was associated with greater odds of in-hospital mortality, when indexed to ABW (adj-OR, 1.17; 95% CI, 1.10–1.25; p < 0.001), IBW (adj-OR, 1.13; 95% CI, 1.09–1.18; p < 0.001), and Adj-BW (adj-OR, 1.19; 95% CI, 1.13–1.27; p < 0.001). CONCLUSIONS: Among critically ill adults with AKI receiving CRRT, obesity appears to confer greater risk of in-hospital mortality, and greater prescribed CRRT dose-intensity was consistently associated with greater mortality risk across all weight-based indices. These findings highlight the potential necessity for modifying CRRT prescription practices among obese patients and highlight the need for further research on optimal CRRT dose-intensity prescription across a broad spectrum of critically ill patients. TRIAL REGISTRATION: This study was prospectively registered on ClinicalTrials.gov (NCT02034448) on January 10, 2014.
参考来源
- Kusirisin P, Lambert JW, Rewa OG, et al. Association between obesity and kidney outcomes in critically ill patients with acute kidney injury receiving continuous renal replacement therapy: a secondary analysis of the multicenter CRRTnet study. Crit Care. 2026. PMID: 41904566. doi:10.1186/s13054-026-05950-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。